The combination of a strong beat, raised guidance, and first-ever share repurchase program signals management confidence in sustained growth. Monitor MACI biopsy/implant trends and progress on UK MHRA submission for further upside catalysts.
Price Chart
Executive Summary
Vericel reported Q2 2026 revenue of $77.5M (+22% YoY), beating consensus of $72.7M, and GAAP EPS of $0.04 vs -$0.01 a year ago and consensus -$0.03. The company raised full-year 2026 revenue guidance to $330-340M and authorized a $200M share repurchase program, its first ever.
Key Financial Metrics
Key Facts
- Total revenue $77.5M, up 22% YoY, vs consensus $72.7M
- GAAP diluted EPS $0.04 vs -$0.01 YoY and consensus -$0.03
- Full-year 2026 revenue guidance raised to $330-340M from $326-336M
- Board authorized $200M share repurchase program
- MACI revenue grew 23% to $65.5M; Burn Care revenue grew 22% to $12.0M
- Net income of $2.2M vs net loss of $0.6M in Q2 2025
- Free cash flow of $14.3M in Q2; $29.4M in H1 2026
- Cash and investments of $227M, no debt
Financial Impact
Revenue beat by ~$4.8M (6.5%) vs consensus; EPS beat by $0.07 vs consensus; guidance raised by $4M at midpoint; $200M buyback represents ~8% of market cap
Risk Factors
- Execution risk on scaling manufacturing at new Burlington facility
- Regulatory and commercial uncertainty for MACI UK approval
- Potential impact of healthcare policy changes on reimbursement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-050815 |
| Document: vcel-20260730.htm | 0001628280-26-050815 |
| Document: 0001628280-26-050815-index-headers.html | 0001628280-26-050815 |
| Document: 0001628280-26-050815-index.html | 0001628280-26-050815 |
| Document: 0001628280-26-050815.txt | 0001628280-26-050815 |
| 8-K Data (Synthetic) | 0001628280-26-050815 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | Insider Cluster | $45.36 $40.89 | ▼ −9.85% | ▼ −9.25% | $39.91 (−12.01%) |
Jul 30, 2026 9w ago | 8-K | $47.61 $41.18 | ▼ −13.51% | ▼ −17.47% | $39.91 (−16.17%) |
Jul 16, 2026 11w ago | Press Release | $47.81 $44.54 | ▼ −6.84% | ▼ −10.46% | $39.91 (−16.52%) |
Jun 30, 2026 13w ago | Insider Cluster | $45.15 $46.62 | ▲ +3.26% | ▲ +5.44% | $39.91 (−11.61%) |
Jun 2, 2026 17w ago | 144 | $34.45 $45.15 | ▲ +31.06% | ▲ +32.62% | $39.91 (+15.85%) |
May 15, 2026 19w ago | Insider Cluster | $34.87 $38.46 | ▲ +10.30% | ▲ +8.71% | $39.91 (+14.45%) |
May 7, 2026 21w ago | 8-K | $35.13 $34.74 | ▼ −1.11% | ▼ −4.25% | $39.91 (+13.61%) |
May 7, 2026 21w ago | Press Release | $35.13 $34.74 | ▼ −1.11% | ▼ −4.25% | $39.91 (+13.61%) |
Apr 23, 2026 23w ago | Press Release | $34.40 $35.40 | ▲ +2.91% | ▼ −1.73% | $39.91 (+16.02%) |
Mar 19, 2026 28w ago | DEFA14A | $32.74 $35.68 | ▲ +8.98% | ▲ +1.36% | $39.91 (+21.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access